knowledge -WSS

knowledge

author：focus 2025-09-27 22:06:15 - browse：29

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： CMS got Medicare Advantage quality rating wrong, judge rules

WSS

Fight over Supreme Court dialysis ruling puts kidney patients at risk

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medicare Advantage proposed rates disappoint insurers

Finland to offer bird flu vaccine to select groups of people, a possible global first

The dental labor crisis is a moment of opportunity

Biogen Alzheimer’s drug launch off to slow start

knowledge

knowledge

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Finland to offer bird flu vaccine to select groups of people, a possible global first

The high cost of giving birth even with insurance

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

In age of alternative facts, a scholarly course on calling out crap

An outdated Medicare rule harms dementia patients with anxiety

After affirmative action ruling, medical educators look to 'holistic review'

Finland to offer bird flu vaccine to select groups of people, a possible global first

Hollywood unions extend contract negotiations for actors

Gilead might be held responsible for not developing a drug

explore

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Key House Republican on health care plans exit from Congress

Sutter Health’s antitrust win overturned by appeals court

Anthony Fauci pushes back on GOP claims during Covid hearing

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

PhRMA lawsuit over Medicare drug price negotiation tossed

focus

hotspot

entertainment

explore